SCHEMBL6090229

SCHEMBL6090229

CN(C)c1ccc(C2NC(=O)c3cccc4c3N2CCC4=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.41
KDM4E B2RXH2 5/20 0.41
MAPT P10636 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 2/20 0.39
RECQL P46063 2/20 0.38
PARP1 P09874 1/20 0.38
ABCB1 P08183 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
TP53 P04637 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
RUNX1 Q01196 1/20 0.37
CBFB Q13951 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089480 0.86 TNKS2 (0.42) ALDH1A1KDM4EMAPTGAAMEN1
SCHEMBL6090523 0.85 TNKS2 (0.39) ALDH1A1KDM4EMAPTPARP1MEN1
SCHEMBL6089877 0.84 PARP1 (0.39) ALDH1A1KDM4EMAPTTDP1PARP1
SCHEMBL6091873 0.84 MEN1 (0.42) ALDH1A1KDM4EMAPTGAAPARP1
SCHEMBL6092226 0.83 TNKS2 (0.45) ALDH1A1KDM4EMAPTTDP1GAA
SCHEMBL6090894 0.81 ATM (0.41) ALDH1A1KDM4EMAPTL3MBTL1TDP1
SCHEMBL6089133 0.81 HTR2C (0.36) ALDH1A1KDM4EPARP1HTR2CHTR2B
SCHEMBL6091636 0.81 PARP1 (0.40) ALDH1A1KDM4EMAPTGAAPARP1
SCHEMBL6090852 0.81 TSHR (0.40) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL6090192 0.80 KMT2A (0.46) ALDH1A1KDM4EMAPTGAARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 ALDH1A1 1890/4885KDM4E 812/4885MAPT 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.